Ely Benaim

Ely Benaim has a wealth of experience in the medical field, spanning over two decades. Ely currently holds the position of Chief Medical Officer and EVP of Development at SonALAsense since April 2023. Prior to this, they served as the Chief Medical Officer at Novocure from April 2019 to January 2023. From February 2015 to March 2019, they held the role of Chief Medical Officer at Rexahn Pharmaceuticals. Before that, they served as the Chief Medical Officer and SVP Regulatory Affairs at BERG Health from June 2013 to January 2015. Ely Benaim also held the position of Senior Director, Clinical Research, Global Clinical Lead at Millennium Pharmaceuticals from March 2011 to June 2013. Ely served as the Vice President of Clinical Affairs at Sangamo BioSciences from April 2007 to August 2010. Earlier in their career, they held various positions at Amgen, Inc., Salmedix, Inc., St. Jude Children's Research Hospital, and the University of Tennessee, Memphis.

Ely Benaim's education history begins with their attendance at Colegio Rambam, although no specific dates or degrees are provided for this period. In 1979, they enrolled at Universidad Central de Venezuela, where they obtained a degree in Medicine. After this, Ely pursued further specialization and completed a Pediatric Residency at the University of South Florida from 1990 to 1993. Following their residency, they continued their education at the University of Tennessee-Health Science Center College of Medicine, where they worked as a Post-Doctoral Research Associate in the field of Hematology/Oncology from 1993 to 1996. Lastly, they served as a Fellow in Bone Marrow Transplantation at St Jude Children's Research Hospital from 1996 to 1997.